What Is Tigan Medication and How Does It Work?

Tigan is a brand name for trimethobenzamide, a prescription antiemetic used to treat nausea and vomiting. Unlike many other anti-nausea medications, trimethobenzamide belongs to its own pharmacological class rather than fitting neatly into the phenothiazine or serotonin-blocker families that dominate the antiemetic market. It has been available for decades, and while it remains an option for some patients, its reputation has shifted over the years as newer drugs have proven more effective for many situations.

What Tigan Is Used For

Trimethobenzamide is approved to treat nausea and vomiting in adults. In practice, it tends to be used when other, more common antiemetics are not an option or have caused problematic side effects. It is sometimes chosen for postoperative nausea, gastroenteritis, or drug-induced nausea. One notable clinical niche is managing the nausea that arises when patients with Parkinson’s disease start treatment with apomorphine, a dopamine agonist that frequently causes severe nausea. A placebo-controlled trial found that trimethobenzamide significantly reduced nausea during the first two months of apomorphine treatment, though the benefit faded by the third month as patients naturally adjusted to the therapy.¹

That Parkinson’s application matters because many standard anti-nausea drugs work by blocking dopamine receptors, which is exactly the wrong approach for someone taking a dopamine-boosting medication. Trimethobenzamide is considered less likely to interfere with dopaminergic therapy, making it a practical choice in that specific context even if it would not be a first-line pick for nausea in general.

How Tigan Works

The exact mechanism of trimethobenzamide is not fully understood. What researchers do know is that it acts centrally in the brain, directly inhibiting a region called the chemoreceptor trigger zone, which sits outside the blood-brain barrier and acts as a surveillance station for toxins in the bloodstream. When this zone detects something it interprets as harmful, it sends signals to the vomiting center in the brainstem. Trimethobenzamide appears to block those emetic impulses before they reach the vomiting center.²

This is different from how many other antiemetics work. Ondansetron (Zofran), for instance, blocks serotonin receptors both centrally and in the gut. Promethazine (Phenergan) and prochlorperazine (Compazine) are phenothiazines that block dopamine, histamine, and acetylcholine receptors broadly, which makes them effective but also responsible for heavy sedation and other side effects. Trimethobenzamide’s narrower action helps explain both its milder side-effect profile and its generally more modest anti-nausea potency.

How It Is Taken

Tigan is available in oral capsule form (typically 300 mg) and as an intramuscular injection (typically 200 mg). The oral capsule is the most common route for outpatient use, usually taken three or four times a day as needed. The injection form is used in clinical settings when a patient cannot keep anything down by mouth, which is obviously a common scenario for someone experiencing severe vomiting.

Trimethobenzamide was previously available as a rectal suppository, but the FDA withdrew approval for the suppository form. The agency concluded there was insufficient evidence that the rectal route was effective. This left the oral and intramuscular forms as the only approved options. If you see references to Tigan suppositories in older medical literature or drug guides, that form is no longer on the market.

One practical consideration with the oral capsule is timing. Taking it on a relatively empty stomach can speed absorption, but if you are already actively vomiting, keeping an oral capsule down long enough for it to work can be difficult. In those cases, the intramuscular injection is the better route, though it requires a healthcare setting or a caregiver trained to give injections.

Side Effects and Risks

Trimethobenzamide is generally considered to have a milder side-effect profile than the phenothiazine antiemetics, which is part of its appeal. The most common side effects include drowsiness, dizziness, and headache. Some patients report diarrhea or muscle cramps. These effects are usually mild and resolve once the medication is stopped.

The more serious concern involves extrapyramidal symptoms, which are involuntary movement problems that can include muscle stiffness, tremor, restlessness, or abnormal posturing. These are the same kinds of movement side effects associated with antipsychotic medications and are related to disruption of dopamine signaling in the brain. While extrapyramidal effects are less common with trimethobenzamide than with the phenothiazines, they can occur, and the risk is higher in certain populations.

Other rare but reported adverse effects include blurred vision, disorientation, seizures (particularly in people with a seizure history), and allergic reactions. Hypotension, or a drop in blood pressure, has also been noted, particularly with the injectable form. If you feel lightheaded or faint after receiving a Tigan injection, that is a known possible reaction worth mentioning to your healthcare provider.

Why Tigan Has a Complicated Reputation

Trimethobenzamide occupies an awkward position in the antiemetic landscape. It is considered less effective than many alternatives, but it also tends to cause fewer side effects than the heavy hitters. This trade-off has led expert panels to take a cautious view. The Beers Criteria, a widely used list of medications considered potentially inappropriate for older adults, specifically flags trimethobenzamide. The panel describes it as “one of the least effective antiemetic drugs” while noting it can still cause extrapyramidal adverse effects, rating the concern as high severity.³

That assessment essentially says the drug does not earn its risks. If an antiemetic is going to carry the possibility of movement-related side effects, the reasoning goes, it should at least be reliably effective at stopping nausea. For older adults, who are already more vulnerable to extrapyramidal symptoms and falls from dizziness, the risk-benefit balance tips unfavorably. This does not mean trimethobenzamide is never appropriate for older patients, but prescribers are encouraged to consider alternatives first.

For younger, otherwise healthy adults, the calculus can be different. When first-line antiemetics are not tolerated or are contraindicated for a specific reason, trimethobenzamide remains a legitimate option. Its continued availability suggests it fills a niche, even if that niche has narrowed considerably over the decades.

Pregnancy and Trimethobenzamide

Nausea during pregnancy is extremely common, and the question of which anti-nausea drugs are safe during pregnancy is something many people need answered. Trimethobenzamide has been used historically during pregnancy, and some older publications suggested it was reasonably safe. However, animal research has raised concerns. A study in neonatal rats found that exposure to trimethobenzamide in utero was associated with growth retardation, neurological damage affecting the developing brain and intestine, and liver damage. The researchers recommended that clinicians perform a careful risk-benefit assessment before prescribing trimethobenzamide during pregnancy.⁴

Animal studies do not always translate directly to human outcomes, and rats metabolize drugs differently than people. But these findings are enough to warrant caution. Most current guidelines for managing nausea and vomiting in pregnancy point toward other options first, particularly doxylamine combined with pyridoxine (vitamin B6), which has a long track record of safety data in pregnant women. Ondansetron is another option sometimes used in pregnancy, though it also carries some debate about potential risks. Trimethobenzamide is not typically considered a go-to choice for morning sickness or hyperemesis gravidarum.

There is also very limited information about whether trimethobenzamide passes into breast milk. Without solid data establishing safety during breastfeeding, the general guidance is to discuss alternatives with your healthcare provider if you are nursing.

How Tigan Compares to Other Antiemetics

The antiemetic market has grown considerably since trimethobenzamide was introduced. Understanding where Tigan fits relative to other options helps explain when and why a prescriber might reach for it.

Ondansetron (Zofran): A serotonin receptor blocker widely used for chemotherapy-induced, postoperative, and general nausea. It is more effective than trimethobenzamide for most indications and has become a standard first-line choice.
Promethazine (Phenergan): A phenothiazine antiemetic that is quite effective but causes significant drowsiness and carries a higher risk of extrapyramidal effects. It is available in oral, injectable, and rectal forms.
Prochlorperazine (Compazine): Another phenothiazine with stronger antiemetic action than trimethobenzamide, but again with more pronounced sedation and movement-related side effects.
Metoclopramide (Reglan): Works by promoting gastric emptying in addition to acting centrally. Effective, but carries a black-box warning for tardive dyskinesia with prolonged use.
Scopolamine: An anticholinergic delivered as a patch behind the ear, mostly used for motion sickness. Causes dry mouth and drowsiness but works through a completely different pathway.

Trimethobenzamide’s main selling point in this lineup is its relatively mild side-effect profile compared to the phenothiazines. For someone who cannot tolerate the sedation from promethazine or the restlessness from metoclopramide, and who has a reason to avoid ondansetron (such as a drug interaction or history of QT prolongation on an electrocardiogram), trimethobenzamide offers a path with fewer complicating factors. The trade-off is that you are getting a less potent antiemetic.

Practical Considerations When Taking Tigan

If your doctor has prescribed trimethobenzamide, a few practical points are worth keeping in mind. The drug can cause drowsiness, so avoid driving or operating heavy machinery until you know how it affects you. Alcohol and other central nervous system depressants can amplify this sedation, so steer clear of combining them.

Because trimethobenzamide can occasionally cause hypotension, standing up slowly from a sitting or lying position is a reasonable precaution, especially in the first few days. This is particularly relevant if you are also taking blood pressure medications.

If you have been prescribed Tigan for a short-term problem like a stomach virus, you will likely take it for only a few days. There is generally no need to taper the dose when stopping. For longer-term use, such as managing nausea from an ongoing medication like apomorphine, follow your prescriber’s guidance on duration. The trial data mentioned earlier suggest that the body often adjusts to the nausea trigger within about two months, at which point the antiemetic can sometimes be discontinued.⁵

Store the oral capsules at room temperature, away from moisture and heat. If you miss a dose and are taking it on a scheduled basis, take it as soon as you remember unless it is nearly time for your next dose. Do not double up.

Why the Suppository Form Was Pulled

The withdrawal of the Tigan suppository is worth understanding because it reflects a broader issue in older drugs. When trimethobenzamide was first approved, the standards for demonstrating effectiveness were less rigorous than they are today. The FDA’s Drug Efficacy Study Implementation (DESI) program, which retroactively evaluated drugs approved before 1962, eventually led to scrutiny of the suppository form. The agency determined that the evidence supporting the effectiveness of rectally administered trimethobenzamide did not meet modern standards. The oral and intramuscular forms survived this review, though even those have been subject to ongoing debate about their overall potency.

This matters for patients because it is a reminder that drug approval is not permanent. If you encounter someone who remembers being prescribed Tigan suppositories years ago, the formulation they recall is no longer available, and switching to a different route of administration is not a simple one-to-one substitution since absorption varies by route.

The Parkinson’s Disease Connection

The relationship between trimethobenzamide and Parkinson’s treatment deserves a closer look because it is one area where this drug has a genuinely useful, distinct role. Apomorphine is a powerful rescue medication for Parkinson’s patients experiencing sudden “off” episodes, periods where their regular medication stops working and movement becomes severely impaired. The problem is that apomorphine frequently causes nausea and vomiting, sometimes severe enough that patients abandon the treatment.

Most antiemetics that block dopamine receptors are off the table for Parkinson’s patients because they would counteract the very dopamine stimulation that treats the disease. Ondansetron works through serotonin receptors and is sometimes used, but trimethobenzamide’s mechanism, which appears to involve the chemoreceptor trigger zone without strongly blocking dopamine, makes it a practical companion to apomorphine therapy. The controlled trial found that trimethobenzamide significantly lowered nausea incidence during the first 28 days and continued to show benefit through day 56, a critical window when patients are most vulnerable to discontinuing apomorphine due to side effects.⁶

By the third month, the difference between trimethobenzamide and placebo was no longer statistically significant, which actually makes clinical sense. Most patients develop tolerance to apomorphine’s nauseating effects over time, so the antiemetic serves primarily as a bridge to get through the adjustment period. That bridge function is valuable: without it, some patients would never make it past the early weeks of apomorphine therapy.

Drug Interactions to Watch For

Trimethobenzamide has relatively few documented drug interactions compared to the phenothiazines, but a few deserve attention. Any medication that causes central nervous system depression, including benzodiazepines, opioids, sleep aids, and antihistamines, can have its sedative effects amplified when combined with trimethobenzamide. If you are taking any of these medications, your doctor may adjust the dose or timing.

There is also a theoretical concern about combining trimethobenzamide with other drugs that can cause extrapyramidal symptoms, such as antipsychotics or metoclopramide. Stacking multiple drugs with this potential raises the likelihood that movement-related side effects will emerge. This combination is generally avoided when possible.

One interaction that is sometimes overlooked involves the use of trimethobenzamide alongside ototoxic drugs, medications that can damage hearing or balance, such as certain antibiotics and loop diuretics. Because trimethobenzamide suppresses nausea and vomiting, it can mask the early symptoms of ototoxicity, namely dizziness and nausea, that would otherwise alert you or your doctor to a problem. If you are taking an ototoxic medication and also using Tigan, your provider should be aware so they can monitor appropriately rather than relying on symptom reports alone.